FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321502867> ?p ?o ?g. }

• W4321502867 endingPage "660" @default.
• W4321502867 startingPage "652" @default.
• W4321502867 abstract "Intravitreal treatment with VEGF inhibitors has proven safe in clinical trials, but often on selected patient groups and without statistical power to investigate rare safety events. Data on anti-VEGF treatment in patients with retinal vein occlusion (RVO) are sparsely represented, and studies providing population-based, long-term follow-up are needed to assess the risks in routine clinical practice. We aimed to evaluate the association between treatment with anti-VEGF and the risk of incident cardiovascular disease (CVD) and all-cause mortality in patients with RVO, and whether this association was affected by selected risk factors. A cohort study from January 2012 to December 2018 using Danish nationwide registries linked on an individual level. Patients with RVO (n = 7235), exposed (n = 3508), and unexposed (n = 3727) to anti-VEGF, aged ≥ 40 years, alive, and living in Denmark. Cox proportional hazards analysis evaluating the effect of intravitreal VEGF inhibitory treatment on incident CVD and all-cause mortality. A predefined analysis plan specified primary outcomes as hazard ratios (HRs) of a composite CVD endpoint and all-cause mortality in patients treated with anti-VEGF compared with untreated. Secondary outcomes included cumulative dose analysis, HRs on subgroups of CVD, and stratified analyses evaluating the effect of sex, age, diabetes, intensive treatment, and preexisting CVD on the HRs. We found no increased risk of composite CVD (HR, 1.07; 95% confidence interval [CI], 0.89–1.29) or all-cause mortality (HR, 0.88; 95% CI, 0.77–1.00) in patients with RVO treated with anti-VEGF. In the secondary analyses, we found no dose-response relationship. We found an increased risk of intracranial hemorrhage (HR, 1.66; 95% CI, 1.02–2.71), but no increased risks in remaining subgroups of CVD. We found no increased risk associated with selected predisposing risk factors, and no increased risk in patients with preexisting CVD. Treatment with anti-VEGF in patients with RVO is safe, when evaluated in a nationwide, population-based setting. An increased risk of intracranial hemorrhage might be present, but cannot be reliably quantified and should be further elucidated by larger population-based studies including all indications for anti-VEGF treatment." @default.
• W4321502867 created "2023-02-23" @default.
• W4321502867 creator A5004747936 @default.
• W4321502867 creator A5018227698 @default.
• W4321502867 creator A5024861911 @default.
• W4321502867 creator A5025647523 @default.
• W4321502867 creator A5059872924 @default.
• W4321502867 creator A5067507410 @default.
• W4321502867 creator A5087636755 @default.
• W4321502867 date "2023-08-01" @default.
• W4321502867 modified "2023-10-18" @default.
• W4321502867 title "VEGF Inhibition in Retinal Vein Occlusion Does Not Associate with Cardiovascular Morbidity or Mortality" @default.
• W4321502867 cites W1851754610 @default.
• W4321502867 cites W1968427420 @default.
• W4321502867 cites W1975058097 @default.
• W4321502867 cites W1978670003 @default.
• W4321502867 cites W1998462298 @default.
• W4321502867 cites W2026216391 @default.
• W4321502867 cites W2037257251 @default.
• W4321502867 cites W2037978728 @default.
• W4321502867 cites W2085712747 @default.
• W4321502867 cites W2121656227 @default.
• W4321502867 cites W2128701654 @default.
• W4321502867 cites W2212725224 @default.
• W4321502867 cites W2219591537 @default.
• W4321502867 cites W2336155211 @default.
• W4321502867 cites W2551469077 @default.
• W4321502867 cites W2578733585 @default.
• W4321502867 cites W2587371977 @default.
• W4321502867 cites W2616361514 @default.
• W4321502867 cites W2767447900 @default.
• W4321502867 cites W2791776334 @default.
• W4321502867 cites W2895211690 @default.
• W4321502867 cites W2965656818 @default.
• W4321502867 cites W3014150789 @default.
• W4321502867 cites W3048155870 @default.
• W4321502867 cites W3110322261 @default.
• W4321502867 cites W3156078512 @default.
• W4321502867 cites W4200334822 @default.
• W4321502867 cites W4297917733 @default.
• W4321502867 doi "https://doi.org/10.1016/j.oret.2023.02.009" @default.
• W4321502867 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36822322" @default.
• W4321502867 hasPublicationYear "2023" @default.
• W4321502867 type Work @default.
• W4321502867 citedByCount "0" @default.
• W4321502867 crossrefType "journal-article" @default.
• W4321502867 hasAuthorship W4321502867A5004747936 @default.
• W4321502867 hasAuthorship W4321502867A5018227698 @default.
• W4321502867 hasAuthorship W4321502867A5024861911 @default.
• W4321502867 hasAuthorship W4321502867A5025647523 @default.
• W4321502867 hasAuthorship W4321502867A5059872924 @default.
• W4321502867 hasAuthorship W4321502867A5067507410 @default.
• W4321502867 hasAuthorship W4321502867A5087636755 @default.
• W4321502867 hasBestOaLocation W43215028671 @default.
• W4321502867 hasConcept C126322002 @default.
• W4321502867 hasConcept C134018914 @default.
• W4321502867 hasConcept C141071460 @default.
• W4321502867 hasConcept C201903717 @default.
• W4321502867 hasConcept C203092338 @default.
• W4321502867 hasConcept C207103383 @default.
• W4321502867 hasConcept C2778257484 @default.
• W4321502867 hasConcept C2778844676 @default.
• W4321502867 hasConcept C2780347916 @default.
• W4321502867 hasConcept C2908647359 @default.
• W4321502867 hasConcept C44249647 @default.
• W4321502867 hasConcept C50382708 @default.
• W4321502867 hasConcept C535046627 @default.
• W4321502867 hasConcept C555293320 @default.
• W4321502867 hasConcept C71924100 @default.
• W4321502867 hasConcept C99454951 @default.
• W4321502867 hasConceptScore W4321502867C126322002 @default.
• W4321502867 hasConceptScore W4321502867C134018914 @default.
• W4321502867 hasConceptScore W4321502867C141071460 @default.
• W4321502867 hasConceptScore W4321502867C201903717 @default.
• W4321502867 hasConceptScore W4321502867C203092338 @default.
• W4321502867 hasConceptScore W4321502867C207103383 @default.
• W4321502867 hasConceptScore W4321502867C2778257484 @default.
• W4321502867 hasConceptScore W4321502867C2778844676 @default.
• W4321502867 hasConceptScore W4321502867C2780347916 @default.
• W4321502867 hasConceptScore W4321502867C2908647359 @default.
• W4321502867 hasConceptScore W4321502867C44249647 @default.
• W4321502867 hasConceptScore W4321502867C50382708 @default.
• W4321502867 hasConceptScore W4321502867C535046627 @default.
• W4321502867 hasConceptScore W4321502867C555293320 @default.
• W4321502867 hasConceptScore W4321502867C71924100 @default.
• W4321502867 hasConceptScore W4321502867C99454951 @default.
• W4321502867 hasIssue "8" @default.
• W4321502867 hasLocation W43215028671 @default.
• W4321502867 hasLocation W43215028672 @default.
• W4321502867 hasOpenAccess W4321502867 @default.
• W4321502867 hasPrimaryLocation W43215028671 @default.
• W4321502867 hasRelatedWork W1727188710 @default.
• W4321502867 hasRelatedWork W2026094606 @default.
• W4321502867 hasRelatedWork W2071306276 @default.
• W4321502867 hasRelatedWork W2119154902 @default.
• W4321502867 hasRelatedWork W2133235702 @default.
• W4321502867 hasRelatedWork W2135028155 @default.
• W4321502867 hasRelatedWork W2203903734 @default.

• next